Renaissance Technologies
MAZE

Renaissance Technologies’s Maze Therapeutics MAZE Stock Holding History

Renaissance Technologies’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$472K Sell
15,800
-11,300
-42% -$499K ﹤0.01% 2627
2025
Q4 		$1.12M Sell
27,100
-59,000
-69% -$2.03M ﹤0.01% 2212
2025
Q3 		$2.23M Buy
+86,100
New +$1.45M ﹤0.01% 1995

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies's MAZE Position: Q1 2026 in Review

Renaissance Technologies reduced its Maze Therapeutics (MAZE) stake by 42% in Q1 2026, selling an estimated $499K and leaving 15,800 shares worth $472K. The position accounts for ﹤0.01% of the portfolio, ranked #2627.

Renaissance Technologies first reported a position in MAZE in Q3 2025 and has held it in 3 quarters since. The position peaked at $2.23M in Q3 2025. 165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

  • Renaissance Technologies held 15,800 shares of Maze Therapeutics worth $472K as of Q1 2026.
  • Renaissance Technologies sold 11,300 Maze Therapeutics shares in Q1 2026, an estimated $499K.
  • Maze Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #2627 holding.
  • Renaissance Technologies first reported a position in Maze Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Renaissance Technologies's Maze Therapeutics position peaked at $2.23M in Q3 2025.
  • 165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.